The Rice D2K Lab wants to help startups and small businesses solve business concerns with data science. Photo courtesy of Rice University

A data-focused lab at Rice University is training the next generation of data scientists. However, the students at the Rice D2K Lab are doing more than just learning about the significance of data, machine learning, and artificial intelligence — they're working as data scientists now.

Businesses — large and small — can come into the lab and have Rice students and faculty work on data projects in both short-term and long-term capacity. One semester, a group of students worked with 311 call data for the city of Houston so that officials can figure out what parts of town were in the most need of support, says Jennifer Sanders, program administrator at the Rice D2K lab.

"They were able to show on a Houston map the areas where most of these 311 calls were coming from," Sanders tells InnovationMap. "That allowed the city to focus on those areas."

Lately, the lab has been focused on a several COVID-19 Houston Response Projects, which addressed issues ranging from homelessness in the time of a pandemic, ventilator distribution, and more. One team even made a recommendation to the city after a data project determined that adding five ambulances to southwest neighborhoods served by the Houston Fire Department Emergency Medical Services program would optimize response times.

The lab has two avenues to help businesses: a semester-long capstone course and a clinic for one-time sessions. This upcoming semester, the capstone course has 60 students signed up to work on 10 to 12 projects from corporate sponsors. These lab members — which support the program monetarily — are selected based on their fit within the program.

The D2K Consulting Clinic also offers free one-hour sessions on campus. At the clinic, students look at the data and assess the possibilities and advise on how to use that data for business gain or growth.

"The consulting clinic can be a starting point if a business is not sure what to do with their data," says Shanna Jin, communications and marketing specialist at the D2K Lab.

The clinic also presents a special opportunity for small businesses and startups, a niche Sanders says they haven't tapped into enough yet. She says most of the companies they've worked with are larger organizations, usually in the energy industry.

"We really want to broaden the scope to smaller startups, tech companies, and nonprofits," Sanders says. "We really don't have to limit ourselves. I would really love to expand our reach."

Membership dues for companies, which provides a more structured, long-term access to data consulting, range from $25,000 to $75,000 a year. However, Sanders says the lab is willing to work with startups on a cost that's more accessible.

Ultimately, the goal of the program is to connect the dots for businesses that have data and don't know how to use it.

"To realize the potential of big data, we need people — people who can transform data to knowledge," says the lab's founder, Genevera Allen, in a promotional video. "That's what we're doing with the Rice D2K Lab."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.